EGFR and lung cancer: Here, we discovered that a specific isoform of type I protein arginine methyltransferases (PRMT), namely, PRMT1, enables lung cancer cells with EGFR or KRASG12C driver mutations and high STAT1 activity to persist through targeted drug treatments.